Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trialRoberto Labianca, Alberto Zaniboni, Alberto F. Sobrero et al.|Annals of Oncology|2010Cited by 110
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.Emilio Bajetta, G. Rosati, Andrea Mambrini et al.|Journal of Clinical Oncology|2012Cited by 15
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al.|Journal of Clinical Oncology|2012Cited by 8
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)Stefano Cascinu, Irene Floriani, Sara Lonardi et al.|European Journal of Cancer|2015Cited by 5
A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab.Stefano Cascinu, Irene Floriani, Gerardo Rosati et al.|Journal of Clinical Oncology|2015Cited by 3